ArticleBioactive materials2027
Hierarchical Nanorocket for spatially coordinated regulation of glycosaminoglycan deposition and metabolism in cartilage.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is characterized by progressive glycosaminoglycan (GAG) depletion caused by insufficient matrix replenishment and excessive proteoglycan catabolism. Here, we developed a spatially coordinated strategy that integrates GAG deposition in the cartilage extracellular matrix (ECM) with intracellular regulation of GAG enrichment and degradation in chondrocytes. To achieve this strategy, we engineered a hierarchical "Nanorocket" comprising a chondroitin sulfate (CS)-cationic peptide Booster and an HDMBr/siADAMTS5 Satellite. The Nanorocket facilitated cartilage penetration and prolonged the intra-articular retention of both components. The Booster supported CS deposition within the cartilage extracellular matrix, whereas the internalized Satellite increased CHPF/CHSY2 expression and silenced ADAMTS5, thereby promoting GAG enrichment while limiting proteoglycan degradation. This coordinated regulation preserved GAG content, reduced matrix porosity, and maintained the mechanical properties of human cartilage explants. In a surgical OA mouse model, periodic treatment preserved cartilage thickness and matrix integrity, mitigated subchondral bone alterations, and improved gait performance. These findings establish the proof-of-concept feasibility of spatially coordinating GAG deposition and metabolism to preserve cartilage homeostasis during early OA progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.